[1] |
马莉娟,何金彩,柴泽英.细胞分化抑制因子-1与细胞增殖核抗原Ki-67在宫颈癌中的表达及相关性研究[J].中国临床药理学杂志,2015,31(8):627-630.
|
[2] |
武雪亮,薛军,王立坤,等.DNA结合分化抑制蛋白1和基质金属蛋白酶9在结直肠癌中的表达及与微血管密度的相关性[J].中国医学科学院学报,2016,38(6): 696-701.
|
[3] |
Ramachandran A, Vizán P, Das D, et al. TGF-β uses a novel mode of receptor activation to phosphorylate SMAD1/5 and induce epithelial-to-mesenchymal transition[J]. Elife, 2018(7):e31756.
|
[4] |
Engerud H, Tangen IL, Berg A, et al. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors[J]. Br J Cancer, 2014, 111(1):78-84.
|
[5] |
Tsang CM, Cheung KC, Cheung YC, et al. Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma[J]. Biochim Biophys Acta, 2015, 1852(3): 2541-2551.
|
[6] |
Cho Y, Cho EJ, Lee JH, et al. Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells[J]. Biomed Pharmacother, 2016(83):607-616.
|
[7] |
Hao L, Liao Q, Tang Q, et al. Id-1 promotes osteosarcoma cell growth and inhibits cell apoptosis via PI3K/AKT signaling pathway[J]. Biochem Biophys Res Commun, 2016, 470(3): 643-649.
|
[8] |
Georgiadou D, Sergentanis TN, Sakellariou S, et al. VEGF and Id-1 in pancreatic adenocarcinoma: prognostic significance and impact on angiogenesis[J]. Eur J Surg Oncol, 2014, 40(10):1331-1337.
|
[9] |
Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2018, 15(10):599-616.
|
[10] |
Chu Q, Jiang Y, Zhang W, et al. Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma[J]. Oncotarget, 2016, 7(51): 84658-84665.
|
[11] |
Harada K, Hirohara J, Ueno Y, et al. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan[J]. Hepatology, 2013, 57(5):1942-1949.
|
[12] |
He M, Qin H, Poon TC, et al. Hepatocellular carcinoma-derived exosomes promote motility of immortalized hepatocyte through transfer of oncogenic proteins and RNAs[J]. Carcinogenesis, 2015, 36(9):1008-1018.
|
[13] |
Feng YX, Wang T, Deng YZ, et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model[J]. Hepatology, 2011, 53(2):483-492.
|
[14] |
Zhu Q, Yuan B, Qiao GL, et al. Prognostic factors for survival after hepatic resection of early hepatocellular carcinoma in HBV-related cirrhotic patients[J]. Clin Res Hepatol Gastroenterol, 2016, 40(4):418-427.
|
[15] |
Papatheodoridis GV, Chan HL, Hansen BE, et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy[J]. J Hepatol, 2015, 62(4):956-967.
|
[16] |
Yang SL, Liu LP, Sun YF, et al. Distinguished prognosis after hepatectomy of HBV-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis[J]. J Gastroenterol, 2016, 51(7):722-732.
|
[17] |
Alzahrani FA, El-Magd MA, Abdelfattah-Hassan A, et al. Potential effect of exosomes derived from cancer stem cells and MSCs on progression of DEN-induced HCC in rats[J]. Stem Cells Int, 2018:8058979.
|
[18] |
Zhang PF, Li KS, Shen YH, et al. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling[J]. Cell Death Dis, 2016(7):e2201.
|
[19] |
Wan X, Cheng C, Shao Q, et al. CD24 promotes HCC progression via triggering Notch-related EMT and modulation of tumor microenvironment[J]. Tumour Biol, 2016, 37(5):6073-6084.
|
[20] |
Kim JS, Choi GH, Jung Y, et al. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines[J]. J Cancer Res Clin Oncol, 2018, 144(8):1487-1501.
|